We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+170.14%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$671M
AUM Growth
+$282M
Cap. Flow
+$43.3M
Cap. Flow %
6.45%
Top 10 Hldgs %
100%
Holding
10
New
3
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$81.5M
2
XFOR icon
X4 Pharmaceuticals
XFOR
+$19.7M
3
SVRA icon
Savara
SVRA
+$6.17M
4
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$1.26M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$65.4M

Sector Composition

Rank Sector Weight
1 Healthcare 84.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$280M 41.8%
7,281,307
– –
CNST
2
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$133M 19.84%
+2,823,529
New +$81.5M
DRNA
3
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$89.9M 13.41%
4,080,237
-3,250,000
-44% -$65.4M
DVAX
4
DELISTED
Dynavax Technologies
DVAX
$48.3M 7.21%
8,452,235
– –
REPL icon
5
Replimune Group
REPL
$1.01B
$40.7M 6.08%
2,838,968
– –
SVRA icon
6
Savara
SVRA
$1.19B
$23M 3.43%
+5,128,593
New +$6.17M
XFOR icon
7
X4 Pharmaceuticals
XFOR
$460M
$17.6M 2.63%
+54,950
New +$19.7M
SLDB icon
8
Solid Biosciences
SLDB
$900M
$17.2M 2.57%
258,078
– –
MRNS
9
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$12.8M 1.91%
1,485,684
+225,000
+18% +$1.26M
APTX
10
DELISTED
Aptinyx Inc. Common Stock
APTX
$7.61M 1.13%
2,225,092
– –

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q4 2019 Portfolio in Review

As of Q4 2019, Bain Capital Life Sciences Investors held 10 positions worth $671M, up 73% from $388M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Bain Capital Life Sciences Investors deployed $43.3M of net new capital in Q4 2019, opening 3 new positions and adding to 1 existing holding. Its largest new stake was Constellation Pharmaceuticals, Inc.: 2,823,529 shares worth $133M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 71% a quarter earlier.

On the sell side, the largest reduction was Dicerna Pharmaceuticals, Inc., an estimated $65.4M trimmed.

  • Bain Capital Life Sciences Investors's largest Q4 2019 buy was Constellation Pharmaceuticals, Inc.: 2,823,529 shares worth $133M.
  • Bain Capital Life Sciences Investors added most to Marinus Pharmaceuticals, Inc in Q4 2019, an estimated $1.26M increase.
  • Bain Capital Life Sciences Investors's biggest Q4 2019 reduction was Dicerna Pharmaceuticals, Inc., cutting an estimated $65.4M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 100% of its $671M portfolio in Q4 2019.
  • Bain Capital Life Sciences Investors opened 3 new positions and closed 0 in Q4 2019.
  • Bain Capital Life Sciences Investors's portfolio value rose 73% quarter-over-quarter to $671M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2019, filed 14 Feb 2020.